1. Business plan: “Structure Biology-Contract Research Organisation”
Our firm intends to be a collaborative, innovative provider of Gene-to-Structure products and services to the global life sciences and pharmaceutical industry, striving to accelerate the process of Structure-Based Drug Discovery (SBDD)”.

2. Corporation Overview Mission
“Structures Private limited intends to be a collaborative, innovative provider of Gene-to-Structure products and services to the global life sciences and pharmaceutical industry, striving to accelerate the process of Structure-Based Drug Discovery”.
Vision
To be among the top 10 companies in India to work for.
To acquire and maintain top 3 leadership position in our chosen area of Business in India.
To consolidate our position of leadership in India in the area of structural biology services to establish global presence.
Continuously create new opportunities for growth in our strategic business and create added value for the customers.

3. Personal Profile RAJIV TYAGI
Gender; Male DOB: 23/02/ Citizenship (dual): Australia/India
EDUCATION
, Ph.D. in Biochemistry/Protein crystallography University of Queensland (UQ), Brisbane, Australia
, Master of Biotechnology
Griffith University, Brisbane, Australia
, Bachelor of Microbiology (Hons.)
University of Delhi, Delhi, India
PROFESSIONAL EXPERIENCE
Presently, Senior Scientist
Structural Biology Division, Jubilant Biosys Limited , Bangalore, India
,Postdoctoral Research Associate
Biology Department, Brookhaven National Laboratory, Upton, New York, USA
, Research officer
Tumor Immunology Laboratory, Queensland Institute of Medical Research, Brisbane, Australia
, Research Fellow
Centre for Biotechnology, Birla Institute of Technology & Sciences (BITS), Rajasthan, India

4. Executive Summary
Our firm intends to be a collaborative, innovative provider of Gene-to-Structure products and services to the global life sciences and pharmaceutical industry, striving to accelerate the process of Structure-Based Drug Discovery (SBDD)”.
The aim of the company is to eventually have presence across the pharmaceuticals value chain of drug discovery services and contract research. The core competence of the company will be in Structure Based Drug Design. The Structural Biology Roadmap will be a strategic effort to create a "picture" gallery of the molecular shapes of proteins in the body. This research approach will involve the development of rapid, efficient, and dependable methods to produce protein samples that scientists can use to determine the three-dimensional structure, or shape, of a protein. The new effort will catalyze what is currently a hit-or-miss process into a organized, coordinated, systematic and streamlined routine, helping researchers clarify the role of protein shape in health and disease.

5. Executive Summary
A limiting step in the determination of protein structures is the production of purified samples of the proteins in sufficient quantities for structural determination. Our company will forge a new chapter in bridging this limitation by scientific innovation to bring accelerated results. In addition continuously create new opportunities for growth in our strategic business and create added value.
Structures require an investment partner for investment of INR 350 lakhs.

6. Challenges to Global Pharmaceutical
Late drug discovery- Even though the industry today uses cutting edge technology to speed up the process of drug in market, there still are plenty of challenges. The companies are very critical of having new drugs to replace the existing top sellers. A new top selling drug can help the company maintain its lead in the segment.
High cost and risk- The pharmaceutical is a high risk business and involves discovery process which is lengthy. It usually takes years for a drug to come to market from initial compound identification. The cost for new drug in market could be between million dollars. This has given big companies virtual monopoly in their own market.
Structural Biology Points the Way to Important Medicines. Structure Based drug Design can shorten the time required for a new drug discovery as well as can reduce the overall cost.
With more than 56,000 protein structures available in the Protein Data Bank (PDB), this number still represents less than 1% of the total number of protein sequences (over 7 million) cataloged in the current release of the UniProt protein knowledgebase (2009).

7. Challenges to Global Pharmaceutical
If we are to have a better understanding of protein function and protein evolution, strategies are needed to ensure that the range of protein structures in the protein universe is more adequately covered.
Until recent breakthroughs in knowledge of the human genome, almost all drugs targeted the same 500 proteins. With increased genomic information it has become known that approximately 10,000 proteins are therapeutically relevant potential drug targets. The world-wide demand by researchers for protein structures is growing rapidly. Structures is set up to determine increasing numbers of protein structures for pharmaceutical companies as this demand continues to grow.

8. Role of structure biology in SBDD
In structure-based drug design, scientists marry computer modeling with protein structure data. The idea is to map every crevice of a protein target of a disease in order to design ways to stop the protein from working. An important component of the technique is finding and/or tailor-making small molecules to "fit" the protein's shape.
The Structural Biology Roadmap will be a strategic effort to create a "picture" gallery of the molecular shapes of proteins in the body. This research approach will involve the development of rapid, efficient, and dependable methods to produce protein samples that scientists can use to determine the three-dimensional structure, or shape, of a protein. The new effort will catalyze what is currently a hit-or-miss process into a organized, coordinated, systematic and streamlined routine, helping researchers clarify the role of protein shape in health and disease.
A limiting step in the determination of protein structures is the production of purified samples of the proteins in sufficient quantities for structural determination. Our firm will forge a new chapter in bridging this limitation by scientific innovation to bring accelerated results. In addition continuously create new opportunities for growth in our strategic business and create added value.

9. Market
The biotech industry in India crossed the $2-billion mark with exports surpassing the $1.2 billion mark, the industry registered nearly 31 percent growth in In it further grew 24%.
There are two companies in India at the moment involved in the Gene to structure services.
Other potential players / competitors in the future could be hardly one or two looking at the present scenario.
The biggest entry barrier in Gene to structure services is the limited talent pool available in the field of Gene to structure Services (SBDD) worldwide, and in India and also the functional knowledge of SBDD process.

10. Service Offering
The aim of the company is to eventually have presence across the pharmaceuticals value chain of drug discovery services and custom research with core competency in Structure based drug design.
Our venture is planning to offer following broad range services
Crystal image annotation
Protein structure refinement
Gene to Structure services
Protein to structure services
Other structural biology related services

11. Strategy Business Model
Type 1- FTE based arrangement- In this arrangement scientists will be dedicated for a particular customer and would not be used for any other work.
Type 2- Project base arrangement- In this arrangement customer will make an initial payment as project initiation fee and pay the balance after the completion of project.
Type 3- Milestone based payment- In this arrangement the payment will be based on the achievement of pre agreed milestones and success factors.

12. Investment Opportunity
We require an investment partner for investment of a INR 350 lakh
Looking for a investor, who can provide full or partial fund for starting up the business and then provide remaining fund in the second stage and third stage.
We need funding for the start-up in three phases:
First = 50,00000 INR to set up infrastructure
Second= 20,00,0000 INR for instrumentation
Third = 50,00,000 as running costs.